CP
ABVX icon

Caligan Partners’s Abivax ABVX Stock Holding History

Caligan Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208M Buy
1,557,924
+96,000
+7% +$10.9M 9.77% 3
2026
Q1 		$163M Buy
1,461,924
+10,000
+0.7% +$1.18M 10.83% 2
2025
Q4 		$196M Hold
1,451,924
– – 16.12% 2
2025
Q3 		$123M Sell
1,451,924
-222,476
-13% -$13.6M 16.15% 2
2025
Q2 		$12.8M Buy
1,674,400
+405,281
+32% +$2.64M 2.46% 10
2025
Q1 		$7.93M Buy
1,269,119
+516,952
+69% +$3.5M 1.66% 13
2024
Q4 		$5.51M Buy
+752,167
New +$6.92M 1.39% 12

Other funds holding ABVX

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Caligan Partners's ABVX Position: Q2 2026 in Review

Caligan Partners increased its Abivax (ABVX) stake by 6.6% in Q2 2026, buying an estimated $10.9M and bringing the position to 1,557,924 shares worth $208M. The position accounts for 9.77% of the portfolio, ranked #3.

Caligan Partners first reported a position in ABVX in Q4 2024 and has held it in 7 quarters since. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Caligan Partners held 1,557,924 shares of Abivax worth $208M as of Q2 2026.
  • Caligan Partners bought 96,000 Abivax shares in Q2 2026, an estimated $10.9M.
  • Abivax made up 9.77% of Caligan Partners's portfolio in Q2 2026, its #3 holding.
  • Caligan Partners first reported a position in Abivax in Q4 2024 and has held it in 7 quarters since.
  • 304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.